Header Logo

Connection

Ian Sanne to Anti-HIV Agents

This is a "connection" page, showing publications Ian Sanne has written about Anti-HIV Agents.
Connection Strength

6,967
  1. Varying intervals of antiretroviral medication dispensing to improve outcomes for HIV patients (The INTERVAL Study): study protocol for a randomized controlled trial. Trials. 2017 Oct 13; 18(1):476.
    View in: PubMed
    Score: 0,308
  2. Cohort profile: the Right to Care Clinical HIV Cohort, South Africa. BMJ Open. 2017 06 10; 7(6):e015620.
    View in: PubMed
    Score: 0,301
  3. Impact of three empirical anti-tuberculosis treatment strategies for people initiating antiretroviral therapy. Int J Tuberc Lung Dis. 2014 Nov; 18(11):1340-6.
    View in: PubMed
    Score: 0,251
  4. Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One. 2014; 9(10):e110252.
    View in: PubMed
    Score: 0,251
  5. A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. HIV Med. 2014 Jan; 15(1):3-12.
    View in: PubMed
    Score: 0,232
  6. The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa. PLoS One. 2013; 8(8):e71719.
    View in: PubMed
    Score: 0,231
  7. Impact of nutritional supplementation on immune response, body mass index and bioelectrical impedance in HIV-positive patients starting antiretroviral therapy. Nutr J. 2013 Aug 06; 12:111.
    View in: PubMed
    Score: 0,231
  8. Tenofovir use and pregnancy among women initiating HAART. AIDS. 2012 Nov 28; 26(18):2393-7.
    View in: PubMed
    Score: 0,220
  9. Treatment outcomes after 7 years of public-sector HIV treatment. AIDS. 2012 Sep 10; 26(14):1823-8.
    View in: PubMed
    Score: 0,217
  10. Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol. 2013 Apr; 42(2):430-9.
    View in: PubMed
    Score: 0,210
  11. Least among equals. Clin Infect Dis. 2012 Mar; 54(6):876-7.
    View in: PubMed
    Score: 0,209
  12. Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS One. 2011; 6(8):e22778.
    View in: PubMed
    Score: 0,201
  13. Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment. PLoS One. 2010 Sep 14; 5(9):e12731.
    View in: PubMed
    Score: 0,189
  14. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):500-6.
    View in: PubMed
    Score: 0,183
  15. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health. 2008 Aug; 13(8):1005-15.
    View in: PubMed
    Score: 0,162
  16. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr. 2008 Jul 01; 48(3):334-44.
    View in: PubMed
    Score: 0,162
  17. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005 Mar 15; 191(6):825-9.
    View in: PubMed
    Score: 0,128
  18. Research as a path to wide-scale implementation of antiretroviral therapy in Africa. J HIV Ther. 2004 Sep; 9(3):65-8.
    View in: PubMed
    Score: 0,124
  19. Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts. Sci Rep. 2022 07 26; 12(1):12715.
    View in: PubMed
    Score: 0,107
  20. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem? Int J Infect Dis. 2001; 5(1):43-8.
    View in: PubMed
    Score: 0,096
  21. Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial. J Acquir Immune Defic Syndr. 2020 11 01; 85(3):280-291.
    View in: PubMed
    Score: 0,095
  22. Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. AIDS. 2020 04 01; 34(5):681-686.
    View in: PubMed
    Score: 0,092
  23. Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia. AIDS. 2020 03 01; 34(3):475-479.
    View in: PubMed
    Score: 0,091
  24. Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. AIDS. 2019 11 01; 33(13):2049-2059.
    View in: PubMed
    Score: 0,089
  25. Treatment outcomes among HIV-positive orphaned and non-orphaned children on antiretroviral therapy in Johannesburg, South Africa. S Afr Med J. 2019 Aug 28; 109(9):679-685.
    View in: PubMed
    Score: 0,088
  26. Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: A model of uptake and adherence to care. PLoS One. 2018; 13(8):e0201955.
    View in: PubMed
    Score: 0,082
  27. Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. PLoS One. 2017; 12(10):e0186557.
    View in: PubMed
    Score: 0,077
  28. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial. AIDS. 2017 Jul 17; 31(11):1611-1619.
    View in: PubMed
    Score: 0,076
  29. Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa. Trop Med Int Health. 2017 02; 22(2):241-251.
    View in: PubMed
    Score: 0,073
  30. Treatment Outcomes and Costs of Providing Antiretroviral Therapy at a Primary Health Clinic versus a Hospital-Based HIV Clinic in South Africa. PLoS One. 2016; 11(12):e0168118.
    View in: PubMed
    Score: 0,073
  31. Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. Trop Med Int Health. 2017 02; 22(2):221-231.
    View in: PubMed
    Score: 0,073
  32. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469.
    View in: PubMed
    Score: 0,071
  33. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Med. 2016 May; 13(5):e1002015.
    View in: PubMed
    Score: 0,070
  34. Brief Report: Does Most Mortality in Patients on ART Occur in Care or After Lost to Follow-Up? Evidence From the Themba Lethu Clinic, South Africa. J Acquir Immune Defic Syndr. 2015 Nov 01; 70(3):323-8.
    View in: PubMed
    Score: 0,067
  35. The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. J Int AIDS Soc. 2014; 17:19065.
    View in: PubMed
    Score: 0,063
  36. Impact of systematic HIV testing on case finding and retention in care at a primary care clinic in South Africa. Trop Med Int Health. 2014 Dec; 19(12):1411-9.
    View in: PubMed
    Score: 0,062
  37. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health. 2014 May; 19(5):490-8.
    View in: PubMed
    Score: 0,060
  38. Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. J Int AIDS Soc. 2014; 17:18651.
    View in: PubMed
    Score: 0,060
  39. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013 Nov 19; 16:18794.
    View in: PubMed
    Score: 0,059
  40. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013 Nov 15; 208(10):1624-8.
    View in: PubMed
    Score: 0,058
  41. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93.
    View in: PubMed
    Score: 0,056
  42. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS. 2013 Feb 20; 27(4):645-50.
    View in: PubMed
    Score: 0,056
  43. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):e55-7.
    View in: PubMed
    Score: 0,056
  44. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25.
    View in: PubMed
    Score: 0,054
  45. Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr. 2012 Aug 15; 60 Suppl 3:S96-104.
    View in: PubMed
    Score: 0,054
  46. Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses. Int J Tuberc Lung Dis. 2012 Oct; 16(10):1358-64.
    View in: PubMed
    Score: 0,054
  47. Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals. AIDS. 2012 Jul 17; 26(11):1355-62.
    View in: PubMed
    Score: 0,054
  48. Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification. PLoS Med. 2012; 9(4):e1001207.
    View in: PubMed
    Score: 0,053
  49. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
    View in: PubMed
    Score: 0,051
  50. Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. AIDS. 2011 Oct 23; 25(16):2027-36.
    View in: PubMed
    Score: 0,051
  51. Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa. J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb; 11(1):57-65.
    View in: PubMed
    Score: 0,051
  52. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011 Sep 17; 11:244.
    View in: PubMed
    Score: 0,051
  53. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011 Aug 24; 25(13):1603-9.
    View in: PubMed
    Score: 0,050
  54. Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study. J Int AIDS Soc. 2011 Jul 29; 14:37.
    View in: PubMed
    Score: 0,050
  55. Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS One. 2011; 6(6):e21450.
    View in: PubMed
    Score: 0,050
  56. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc. 2011 May 15; 14:24.
    View in: PubMed
    Score: 0,049
  57. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):349-55.
    View in: PubMed
    Score: 0,049
  58. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011 Jan 01; 52(1):128-37.
    View in: PubMed
    Score: 0,048
  59. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
    View in: PubMed
    Score: 0,048
  60. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):480-4.
    View in: PubMed
    Score: 0,046
  61. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009 Jun 01; 48(11):1617-23.
    View in: PubMed
    Score: 0,043
  62. Characteristics of patients accessing care and treatment for HIV/AIDS at public and nongovernmental sites in South Africa. J Int Assoc Physicians AIDS Care (Chic). 2008 Jul-Aug; 7(4):200-7.
    View in: PubMed
    Score: 0,041
  63. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr. 2007 Sep 01; 46(1):91-100.
    View in: PubMed
    Score: 0,038
  64. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006 Sep 15; 43(6):783-6.
    View in: PubMed
    Score: 0,036
  65. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004 Jul 15; 190(2):280-4.
    View in: PubMed
    Score: 0,031
  66. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003 Dec 05; 17(18):2603-14.
    View in: PubMed
    Score: 0,030
  67. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis. 2003 Dec 01; 188(11):1652-8.
    View in: PubMed
    Score: 0,029
  68. T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment. AIDS. 2003 May 23; 17(8):1145-9.
    View in: PubMed
    Score: 0,028
  69. Challenges in delivering antiretroviral treatment in resource poor countries. AIDS. 2002; 16 Suppl 4:S177-87.
    View in: PubMed
    Score: 0,026
  70. Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial. Lancet Glob Health. 2021 05; 9(5):e628-e638.
    View in: PubMed
    Score: 0,025
  71. Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Serv Res. 2017 Jan 17; 17(1):41.
    View in: PubMed
    Score: 0,018
  72. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
    View in: PubMed
    Score: 0,018
  73. Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis. 2014 Jun; 23:56-62.
    View in: PubMed
    Score: 0,015
  74. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
    View in: PubMed
    Score: 0,014
  75. Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):e39-46.
    View in: PubMed
    Score: 0,014
  76. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
    View in: PubMed
    Score: 0,013
  77. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol. 2011 Oct; 17(5):438-47.
    View in: PubMed
    Score: 0,013
  78. The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc. 2010 Dec 07; 13:49.
    View in: PubMed
    Score: 0,012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.